Search research articles
Contact Us
Filters
Showing results (51-60 of 75) with videos related to
Page
of 8
Sort By:
The Journal of Urology
|
June 24, 1999
Intrinsic drug resistance in primary and metastatic renal cell carcinoma
E Gamelin, S D Mertins, J T Regis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2002
Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study
C Louvet, T André, G Lledo, et al.
British Journal of Cancer
|
May 29, 2003
Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer
A Lortholary, T Delozier, A Monnier, et al.
British Journal of Cancer
|
August 17, 2001
Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
M A Bensmaïne, M Marty, A de Gramont, et al.
Anti-Cancer Drugs
|
June 13, 1998
Determination of unbound platinum after oxaliplatin administration: comparison of currently available methods and influence of various parameters
E Gamelin, M Boisdron-Celle, A Lebouil, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 30, 2000
Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients
Bensmaïne, A de Gramont, S Brienza, et al.
Cancer
|
July 27, 1999
Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot study
P Menei, M C Venier, E Gamelin, et al.
Clinical Pharmacology and Therapeutics
|
October 3, 2000
Dose and time dependencies of 5-fluorouracil pharmacokinetics
C Terret, E Erdociain, R Guimbaud, et al.
Clinical Pharmacology and Therapeutics
|
January 12, 2017
A Pharmacokinetic and Safety Study of Trebananib, an Fc-Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction
B Wu, L D Lewis, R D Harvey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 1, 1997
Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients
E Gamelin, A L Bouil, M Boisdron-Celle, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 75) with videos related to
Sort By:
Page
of 8
The Journal of Urology
|
June 24, 1999
Intrinsic drug resistance in primary and metastatic renal cell carcinoma
E Gamelin, S D Mertins, J T Regis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2002
Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study
C Louvet, T André, G Lledo, et al.
British Journal of Cancer
|
May 29, 2003
Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer
A Lortholary, T Delozier, A Monnier, et al.
British Journal of Cancer
|
August 17, 2001
Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
M A Bensmaïne, M Marty, A de Gramont, et al.
Anti-Cancer Drugs
|
June 13, 1998
Determination of unbound platinum after oxaliplatin administration: comparison of currently available methods and influence of various parameters
E Gamelin, M Boisdron-Celle, A Lebouil, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 30, 2000
Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients
Bensmaïne, A de Gramont, S Brienza, et al.
Cancer
|
July 27, 1999
Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot study
P Menei, M C Venier, E Gamelin, et al.
Clinical Pharmacology and Therapeutics
|
October 3, 2000
Dose and time dependencies of 5-fluorouracil pharmacokinetics
C Terret, E Erdociain, R Guimbaud, et al.
Clinical Pharmacology and Therapeutics
|
January 12, 2017
A Pharmacokinetic and Safety Study of Trebananib, an Fc-Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction
B Wu, L D Lewis, R D Harvey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 1, 1997
Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients
E Gamelin, A L Bouil, M Boisdron-Celle, et al.
Page
of 8